This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Merck Patent Gmbh, Pfizer Corporation. Active years: 2020-2026.
Company Filing History:
3 out of 3,020 
1 out of 4,486 
Years Active: 2020-2026
Title: Heike Dahmen: Innovator in Cancer Treatment
Introduction
Heike Dahmen is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic combinations. With a total of 3 patents, her work focuses on enhancing the efficacy of cancer therapies.
Latest Patents
Dahmen's latest patents include a groundbreaking combination of a PD-1 antagonist, an ATR inhibitor, and a platinating agent for the treatment of cancer. This invention relates to combination therapies that are particularly useful in treating cancer. The therapeutic combination aims to improve patient outcomes by targeting multiple pathways involved in cancer progression. Another notable patent is for a diagnostic anti-PD-L1 antibody, which binds to an epitope within human PD-L1 with high specificity and reproducibility. This antibody can be utilized in assessing PD-L1 expression in tissue samples, aiding in patient stratification and treatment decisions.
Career Highlights
Throughout her career, Heike Dahmen has worked with leading pharmaceutical companies, including Merck Patent GmbH and Pfizer Corporation. Her experience in these organizations has allowed her to collaborate with some of the brightest minds in the industry, further enhancing her contributions to cancer research.
Collaborations
Some of her notable coworkers include Claudia Wilm and Klaus Schneider, who have played a role in her innovative projects and research endeavors.
Conclusion
Heike Dahmen's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. Her patents and collaborations highlight her commitment to advancing therapeutic options for patients.